Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients

NCT04350177 is registered in ClinicalTrials.gov with ABLi Therapeutics, Inc. as lead sponsor.

NCT NCT04350177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04350177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Determine the Safety, Tolerability and Pharmacokinetics (PK) of IkT-148009 in Older Adult and Elderly Healthy Volunteers With Extension Into Parkinson's Patients
Lead sponsor
ABLi Therapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 16, 2021
Completion date
January 30, 2023
Enrollment
101 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy elderly, parkinson disease